Bioactive sphingolipids in the pathogenesis of chronic obstructive pulmonary disease

Kengo Koike, Evgeny V. Berdyshev, Russell P. Bowler, April K. Scruggs, Danting Cao, Kelly S. Schweitzer, Karina A. Serban, Irina Petrache

Research output: Contribution to journalArticle

Abstract

A better understanding of the pathogenesis of distinct chronic obstructive pulmonary disease (COPD) phenotypes will improve diagnostic and therapeutic options for this common disease. We present evidence that sphingolipids such as ceramides are involved in the emphysema pathogenesis. Whereas distinct ceramide species cause cell death by apoptosis and necroptosis, cell adaptation leads to accumulation of other sphingolipid metabolites that extend cell survival by triggering autophagy. Cigarette smoke-released sphingolipids have been involved in both the initiation and persistence of lung injury via intracellular signaling and paracrine effects mediated via exosomes and plasma membrane-bound microparticles. Strategies to control sphingolipid metabolite production may promote cellular repair and maintenance to treat COPD.

Original languageEnglish (US)
Pages (from-to)S249-S252
JournalAnnals of the American Thoracic Society
Volume15
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

Sphingolipids
Chronic Obstructive Pulmonary Disease
Ceramides
Paracrine Communication
Exosomes
Autophagy
Emphysema
Lung Injury
Smoke
Tobacco Products
Cause of Death
Cell Survival
Cell Death
Maintenance
Cell Membrane
Apoptosis
Phenotype
Therapeutics

Keywords

  • Ceramide
  • Emphysema
  • Sphingosine-1 phosphate

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Bioactive sphingolipids in the pathogenesis of chronic obstructive pulmonary disease. / Koike, Kengo; Berdyshev, Evgeny V.; Bowler, Russell P.; Scruggs, April K.; Cao, Danting; Schweitzer, Kelly S.; Serban, Karina A.; Petrache, Irina.

In: Annals of the American Thoracic Society, Vol. 15, 01.12.2018, p. S249-S252.

Research output: Contribution to journalArticle

Koike, Kengo ; Berdyshev, Evgeny V. ; Bowler, Russell P. ; Scruggs, April K. ; Cao, Danting ; Schweitzer, Kelly S. ; Serban, Karina A. ; Petrache, Irina. / Bioactive sphingolipids in the pathogenesis of chronic obstructive pulmonary disease. In: Annals of the American Thoracic Society. 2018 ; Vol. 15. pp. S249-S252.
@article{fe84dd580b3742e184d6d8a707dd026b,
title = "Bioactive sphingolipids in the pathogenesis of chronic obstructive pulmonary disease",
abstract = "A better understanding of the pathogenesis of distinct chronic obstructive pulmonary disease (COPD) phenotypes will improve diagnostic and therapeutic options for this common disease. We present evidence that sphingolipids such as ceramides are involved in the emphysema pathogenesis. Whereas distinct ceramide species cause cell death by apoptosis and necroptosis, cell adaptation leads to accumulation of other sphingolipid metabolites that extend cell survival by triggering autophagy. Cigarette smoke-released sphingolipids have been involved in both the initiation and persistence of lung injury via intracellular signaling and paracrine effects mediated via exosomes and plasma membrane-bound microparticles. Strategies to control sphingolipid metabolite production may promote cellular repair and maintenance to treat COPD.",
keywords = "Ceramide, Emphysema, Sphingosine-1 phosphate",
author = "Kengo Koike and Berdyshev, {Evgeny V.} and Bowler, {Russell P.} and Scruggs, {April K.} and Danting Cao and Schweitzer, {Kelly S.} and Serban, {Karina A.} and Irina Petrache",
year = "2018",
month = "12",
day = "1",
doi = "10.1513/AnnalsATS.201809-592MG",
language = "English (US)",
volume = "15",
pages = "S249--S252",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",

}

TY - JOUR

T1 - Bioactive sphingolipids in the pathogenesis of chronic obstructive pulmonary disease

AU - Koike, Kengo

AU - Berdyshev, Evgeny V.

AU - Bowler, Russell P.

AU - Scruggs, April K.

AU - Cao, Danting

AU - Schweitzer, Kelly S.

AU - Serban, Karina A.

AU - Petrache, Irina

PY - 2018/12/1

Y1 - 2018/12/1

N2 - A better understanding of the pathogenesis of distinct chronic obstructive pulmonary disease (COPD) phenotypes will improve diagnostic and therapeutic options for this common disease. We present evidence that sphingolipids such as ceramides are involved in the emphysema pathogenesis. Whereas distinct ceramide species cause cell death by apoptosis and necroptosis, cell adaptation leads to accumulation of other sphingolipid metabolites that extend cell survival by triggering autophagy. Cigarette smoke-released sphingolipids have been involved in both the initiation and persistence of lung injury via intracellular signaling and paracrine effects mediated via exosomes and plasma membrane-bound microparticles. Strategies to control sphingolipid metabolite production may promote cellular repair and maintenance to treat COPD.

AB - A better understanding of the pathogenesis of distinct chronic obstructive pulmonary disease (COPD) phenotypes will improve diagnostic and therapeutic options for this common disease. We present evidence that sphingolipids such as ceramides are involved in the emphysema pathogenesis. Whereas distinct ceramide species cause cell death by apoptosis and necroptosis, cell adaptation leads to accumulation of other sphingolipid metabolites that extend cell survival by triggering autophagy. Cigarette smoke-released sphingolipids have been involved in both the initiation and persistence of lung injury via intracellular signaling and paracrine effects mediated via exosomes and plasma membrane-bound microparticles. Strategies to control sphingolipid metabolite production may promote cellular repair and maintenance to treat COPD.

KW - Ceramide

KW - Emphysema

KW - Sphingosine-1 phosphate

UR - http://www.scopus.com/inward/record.url?scp=85058821109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058821109&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201809-592MG

DO - 10.1513/AnnalsATS.201809-592MG

M3 - Article

VL - 15

SP - S249-S252

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

ER -